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Background & aims: Surgical trauma leads to an inﬂammatory response that causes surgical morbidity.
Reduced antioxidant micronutrient (AM)a levels and/or excessive levels of Reactive Oxygen Species
(ROS)b have previously been linked to delayed wound healing and presence of chronic wounds. We
aimed to evaluate the effect of pre-operative supplementation with encapsulated fruit and vegetable
juice powder concentrate (JuicePlusþ®) on postoperative morbidity and Quality of Life (QoL)c.
Methods: We conducted a randomised, double-blind, placebo-controlled two-arm parallel clinical trial
evaluating postoperative morbidity following lower third molar surgery. Patients aged between 18 and
65 years were randomised to take verum or placebo for 10 weeks prior to surgery and during the ﬁrst
postoperative week. The primary endpoint was the between-group difference in QoL over the ﬁrst
postoperative week, with secondary endpoints being related to other measures of postoperative
morbidity (pain and trismus).
Results: One-hundred and eighty-three out of 238 randomised patients received surgery (Intention-To-
Treat population). Postoperative QoL tended to be higher in the active compared to the placebo group.
Furthermore, reduction in mouth opening 2 days after surgery was 3.1 mm smaller (95% CI 0.1, 6.1), the
mean pain score over the postoperative week was 8.5 mm lower (95% CI 1.8, 15.2) and patients were less
likely to experience moderate to severe pain on postoperative day 2 (RR 0.58, 95% CI 0.35, 0.95),
comparing verum to placebo groups.
Conclusion: Pre-operative supplementation with a fruit and vegetable supplement rich in AM may
improve postoperative QoL and reduce surgical morbidity and post-operative complications after
surgery.
Trial registration: ClinicalTrials.gov Identiﬁer: NCT01145820; Registered June 16, 2010.
© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., University of Birmingham, 5
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Surgical removal of lower third molars (wisdom teeth) is one of
the most common surgical procedures. It is associated with marked
postoperative morbidity as a consequence of surgical trauma,
including pain, swelling and reduced mouth opening (trismus)
[1,2]. Whilst it is recognised that there is signiﬁcant inter-individual
variability in postoperative morbidity, patient-level determinants
remain poorly understood.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
mentation with a fruit and vegetable juice powder concentrate and
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Abbreviations
a AM Antioxidant Micronutrients
b ROS Reactive Oxygen Species
c QoL Quality of Life
d GSH Tripeptide Reduced Glutathione
e GSSG non-radical form of Glutathione
f Nrf2 Nuclear Factor E2 (Erythroid 2)-Related Factor 2
g F&V Fruit and Vegetable ¼ active group
h VAS Visual Analogue Scale
i PoSSe Postoperative Symptom Severity
j BMI Body Mass Index
k SMAC Small Molecule Antioxidant Capacity
l AE Adverse Event
m SD Standard Deviation
n IQR Interquartile range
o ITT Intention To Treat
p CI Conﬁdence Interval
q GI Gastrointestinal
P. Gorecki et al. / Clinical Nutrition xxx (2017) 1e82Reactive Oxygen Species (ROS)b released by inﬂammatory
cells, in particular neutrophils, play a key role in wound healing,
with normal ROS levels facilitating healing, and excess ROS
creating oxidative stress. Oxidative stress activates major redox-
regulated pro-inﬂammatory signalling cascades via the redox-
sensitive gene transcription factor Nuclear Factor kappa-B
(NFkB), and thus the redox status of healing tissues and their
constituent cells impacts upon wound healing dynamics [3,4]. A
wide variety of antioxidant micronutrients (AM)a are implicated
in regulating the redox environment during wound healing.
Excess ROS are removed by various antioxidant systems working
in concert via redox cycling reactions, such as vitamins E, C and
the non-radical tripeptide, Reduced Glutathione (GSH)d, the ter-
minal stage of which results in the oxidation of GSH to its oxidized
counterpart GSSGe [5]. GSH however, must be synthesised by
cells, a process that requires the activation of the redox-regulated
gene transcription factor Nuclear Factor E2 (Erythroid 2)-Related
Factor 2 (Nrf2)f [6,7]. Whole food nutrition rather than individual
vitamin supplementation is therefore generally recommended in
order to maintain AM in homoeostatic balance and preserve GSH,
which is a powerful regulator of cellular redox state and thus of
key transcriptional events. In acute models of rodent wound
healing, tissue levels of GSH, ascorbate and vitamin E show a
sustained decrease of 60e70% after wounding [8]. Furthermore,
tissue levels of AM are considerably reduced in the wounds of
aged rats relative to young rats [9], and in immunosuppressed rats
compared with immunocompetent animals [10]. Thus, impaired
healing appears to be associated with reduced AM tissue levels
known to affect key redox-regulated signalling pathways, such as
Nrf2 and NFkB.
Given the role of ROS in wound healing and control of infec-
tion, there is a surprising paucity of data on the effect of AM intake
and wound healing, including the incidence of post-surgical
complications/morbidity. Therefore, here we report a double-
blind, placebo-controlled, randomised clinical trial to ascertain
the efﬁcacy of pre-operative supplementation with encapsulated
fruit and vegetable juice powder concentrate to reduce post-
operative morbidity and improve QoL following lower third molar
surgery.Please cite this article in press as: Gorecki P, et al., Perioperative supple
postsurgical morbidity: A double-blind, randomised, placebo-controlle
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2.1. Study design and participants
The FAVOURITE study was a randomised, double-blind, placebo-
controlled two-arm parallel clinical trial conducted at the School of
Dentistry, University of Birmingham and Birmingham Dental Hos-
pital, Birmingham, UK. The study protocol was approved by the
South Staffordshire Local Research Ethics Committee (Reference
09/H1203/82). All enrolled patients provided written informed
consent.
The objective of this study was to evaluate whether encapsulated
fruit and vegetable powder concentrate (JuicePlusþ®, The Juice
Plusþ Company, LLC, Collierville, Tennessee, USA) supplementation,
beginning 10 weeks before surgery, improved postoperative QoL and
reduced postoperative morbidity and complications following lower
third molar surgery compared to placebo.
Patients aged between 18 and 65 years who required the sur-
gical removal of one mandibular third molar were considered
eligible to participate. Patients on long term antimicrobial or anti-
inﬂammatory drugs or taking any vitamin or mineral supple-
ments, patients requiring pre-operative antibiotic prophylaxis,
patients with allergies to any of the ingredients contained in the
active or placebo capsules, patients with a self-reported inability to
swallow the supplied capsules, an inability or unwillingness to give
informed consent, patients requiring additional concomitant tooth
extractions at the time of surgery, pregnant or lactating women,
and patients with any clinically signiﬁcant or unstable physical or
mental condition or disability were excluded from the trial.2.2. Randomisation and allocation concealment
At the baseline visit, following written informed consent and
veriﬁcation of eligibility criteria, eligible patients were assigned the
next available randomisation number and then provided with the
corresponding supplements. Randomisation was carried out using
block randomisation with variable block size in a 1:1 ratio using a
computer algorithm [www.randomization.com]. Test and placebo
capsules were provided to the study centre in consecutively
numbered, identical tubs. Both patients and clinicians were blinded
to group assignment. The randomisation list was not kept at the
study centre andwas not accessible by investigators during the study.2.3. Intervention
The verum test capsules were based on commercially available
formulations of Juice Plusþ® (active, F&Vg) and contained a ﬁne,
granular powder, encapsulated in a size 00 gelatine capsule. The
capsule contained a blended fruit and vegetable pulp and juice
powder concentrate derived from Acerola cherry, apple, beet,
beetroot, broccoli, cabbage, carrot, cranberry, dates, garlic, kale,
orange, peach, papaya, parsley, pineapple, prune, spinach, sugar
beet, tomato, with Spirulina paciﬁca, Lactobacillus acidophilus, rice
bran, oat bran and Dunaliella salina. These active ingredients were
supplemented to provide declared totals (daily dose) of b-Carotene
(7.5 mg), vitamin E (46 mg), vitamin C (200 mg) and folic acid
(400 mg). The amount of polyphenolic AM contained within the
phytonutrient capsules varies according to growing and harvest
conditions, and absolute levels were not analysed. The placebo
(control) capsules were of identical appearance and contained
microcrystalline cellulose.mentation with a fruit and vegetable juice powder concentrate and
d clinical trial, Clinical Nutrition (2017), http://dx.doi.org/10.1016/
P. Gorecki et al. / Clinical Nutrition xxx (2017) 1e8 3Patients were asked to take two capsules, twice daily with food
(¼ four supplements per day) for 10 weeks prior to their surgical
intervention. Following wisdom tooth surgery, participants were
asked to continue taking the study medication for the ﬁrst post-
operative week.
Capsule counts were performed on the day of surgery and at the
ﬁnal study visit, when all remaining capsules were returned to the
study centre.
2.4. Surgery and follow-up
Patients had standard outpatient third molar surgery ten weeks
following randomisation (see online supplement for details on
surgical procedure). Patients received a postoperative diary after
the surgical intervention to record analgesic consumption and pain
intensity on a 10 cm Visual Analogue Scale (VAS)h once daily for 1
week. Additionally, patients were clinically examined 2 days and 1
week (ﬁnal study visit) following surgery (see Study Flow Chart,
Fig. 1).
2.5. Outcome measures
Postoperative QoLwas the primary outcome andwas determined
at the 1-week follow-up visit using the Postoperative Symptom and
Severity (PoSSe)i scale; a self-administered, validated instrument
speciﬁcally designed to evaluate QoL over the ﬁrst postoperativeFig. 1. CONSORT ﬂ
Please cite this article in press as: Gorecki P, et al., Perioperative supple
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seven domains (subscales), including eating, speech, sensation,
appearance, pain, sickness and interferencewith daily activities. The
overall score is a weighted sum of the subscale scores, ranging from
0 to 100 with higher scores indicating worse QoL [2].
Secondary outcomes of morbidity and post-operative compli-
cations included (i) trismus, which represents the reduction in a
patient's mouth opening postoperatively compared to baseline, (ii)
pain intensity during the ﬁrst postoperative week, and (iii) anal-
gesic consumption.
Mouth opening was measured by the clinician as the inter-
incisal distance in mm before surgery and on postoperative day 2
and day 7 using a ruler. Pain intensity and analgesic consumption
were recorded by the patient in the patient diary.
2.6. Other data and laboratory analyses
Recorded demographic and anthropometric data included age,
gender, race/ethnicity, smoking status, weight, height and Body
Mass Index (BMI)j. We assessed a number of tooth- and surgery-
related measures on the day of surgery (see online supplement
for details). Venous blood samples were taken, processed and
stored at all visits for the analysis of a range of micronutrients at the
end of the study. Details regarding blood sampling and laboratory
procedures are described in the online supplement. We estimated
small molecule antioxidant capacity (SMAC)k in serum from serumow diagram.
mentation with a fruit and vegetable juice powder concentrate and
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P. Gorecki et al. / Clinical Nutrition xxx (2017) 1e84concentrations of uric acid and vitamins A, C and E for baseline and
day of surgery as previously described [11].
2.7. Statistical analyses
2.7.1. Primary endpoint and sample size
The primary endpoint was the between-group difference in oral
health-related QoL over the ﬁrst postoperative week assessed with
the PoSSe scale. The study required a minimum of 170 patients
(n ¼ 85 per group) in order to achieve 90% power to detect a stand-
ardised effect size of 0.5 at a signiﬁcance level of a ¼ 0.05, which
would generally be considered a clinically meaningful difference in
QoL between groups [12]. Subjects lost to follow-up were replaced
until the target sample size for the primary endpoint was reached.
2.7.2. Secondary endpoints
Assessment of the following secondary endpoints was
performed:
 Speciﬁc QoL domains (PoSSe subscales),
 Trismus on postoperative day 2 and day 7, i.e., the difference
between the pre-operative interincisal distance on the day of
surgery and the interincisal distance 2 days and 7 days following
surgery, respectively,
 Mean pain score from postoperative days 1 to 6,
 The proportion of patients that reported pain of 50 mm or
higher on day 2 and day 6,
 The proportion of patients experiencing an absolute increase of
20 mm in pain score on any day between postoperative day 4
and day 6, compared to the previous day (a surrogate for alve-
olar osteitis/wound infection),
 The between-group difference in total consumption of analge-
sics during the ﬁrst postoperative week,
 Adverse Events (AEs)l.Table 1
Baseline patient characteristics and micronutrient levels by treatment group.
Placebo (n ¼ 118) F&V (n ¼ 120)
Age, years 26 [24, 32] 28 [24, 34]
Male, n (%) 40 (33.9) 49 (40.8)
Smoking status, n (%)
Never 63 (53.4) 63 (52.5)
Ex-smoker 27 (22.9) 23 (19.2)
Current smoker 28 (23.7) 34 (28.3)
Index of multiple deprivation 34.7 (18.2) 33.6 (18.1)
Systolic Blood Pressure (mmHg) 127.3 (13.0) 128.1 (14.8)
Diastolic Blood Pressure (mmHg) 79.0 (12.4) 79.6 (10.8)
Weight (kg) 75.2 (18.9) 76.4 (16.8)
Height (m) 1.69 (0.11) 1.70 (0.10)
BMI 25.1 [21.8, 28.9] 25.4 [22.2, 30.1]
Race, n (%)
White 72 (61.0) 79 (65.8)
Asian 30 (25.4) 22 (18.3)
Black 9 (7.6) 12 (10.0)
Other 7 (5.9) 7 (5.8)
Micronutrientsa
Vitamin C (mmol/L) 55.2 (25.0) 60.1 (26.4)
Lutein (mmol/L) 0.19 [0.14, 0.25] 0.20 [0.15, 0.26]
Zeaxanthin (mmol/L) 0.05 [0.04, 0.07] 0.05 [0.04, 0.07]
Cryptoxanthin (mmol/L) 0.10 [0.07, 0.17] 0.10 [0.08, 0.15]
Lycopene (mmol/L) 0.87 [0.55, 1.19] 0.76 [0.55, 1.10]
a-Carotene (mmol/L) 0.08 [0.04, 0.12] 0.08 [0.05, 0.11]
b-Carotene (mmol/L) 0.29 [0.18, 0.46] 0.32 [0.23, 0.52]
a-Tocopherol (mmol/L) 20.2 (4.6) 20.9 (5.8)
Retinol (mmol/L) 1.33 (0.33) 1.28 (0.34)
SMAC (mmol/L Teq) 381 [330, 441] 385 [346, 457]
Continuous variables are presented as mean (SD) or median [IQR].
a There is missing baseline data for all micronutrients for 13 patients assigned to
placebo and 13 patients assigned to F&V.2.7.3. Pre-speciﬁed analysis plan
Statistical analysis was performed according to a pre-speciﬁed
analysis plan (see online supplement for details). Brieﬂy, analyses
were done according to the Intention-To-Treat (ITT)o principle,
which included all randomised patients who received the supple-
ments and returned for at least one follow-up appointment. Sum-
mary statistics were calculated as appropriate. For comparisons
between groups for primary and secondary endpoints, we calculated
effect estimates, 95% conﬁdence intervals and p-values for using
appropriate multiple regression models. In addition to unadjusted
estimates, we calculated estimates adjusting for important baseline
characteristics only and estimates adjusting for important baseline
as well as surgical characteristics. Further details, including the
handling of missing data, are described in the online supplement.
2.7.4. Compliance
Compliance was calculated for patients for whom follow-up
capsule counts were available as the proportion of capsules taken
relative to the expected number of capsules taken with 100%
compliance. ‘Good compliance’ was deﬁned as at least 80% of
capsules taken [13,14].
3. Results
3.1. Baseline characteristics
3.1.1. Randomised patients
Patients were enrolled between June 2010 and October 2013. A
total of 248 patients were assessed for eligibility. Eight patients didPlease cite this article in press as: Gorecki P, et al., Perioperative supple
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Therefore, 238 participants were randomised out of which 120
belonged to the active and 118 to the placebo group (Fig.1). Baseline
characteristics of all randomised patients were overall well
balanced between the two treatment arms (Table 1).3.1.2. ITT population
Of the 238 randomized patients, 19 patients allocated to F&V
and 26 patients allocated to placebo did not return for surgery.
Therefore, surgery was performed in 193 participants. A further ten
patients (active n ¼ 3, placebo n ¼ 7) did not return for any follow-
up appointments. Hence, 183 patients had data available for at least
one endpoint (ITT population) (Fig. 1). Detailed descriptions of
patients lost to follow-up and missing data can be found in the
Online Supplemental Material. Brieﬂy, current smokers were less
likely to attend for surgery, and patients with poor oral hygiene and
less extensive surgery were less likely to attend for follow-up after
surgery (Supplemental Table 1). Due to some patients not recording
all required details in their postoperative diary, not returning their
diary, or some participants not attending one of their follow-up
appointments, some endpoint analyses contained less than 183
patient data (Fig. 1). Further details on missing data are presented
in Supplemental Table 2.
Baseline and surgical characteristics of the ITT population were
overall well balanced (Table 2). However, the proportion of current
smokers (29.6% vs 15.3%) and plasma vitamin C concentrations at
baseline (61.4 mmol/L vs 52.9 mmol/L) were higher, and bone
removal was lower (minor bone removal in 28.2% vs. 43.9%) in the
active compared to the placebo group, respectively.3.1.3. Compliance
On average, patients took more than 80% of the assigned cap-
sules. There were no statistically signiﬁcant differences betweenmentation with a fruit and vegetable juice powder concentrate and
d clinical trial, Clinical Nutrition (2017), http://dx.doi.org/10.1016/
Table 2
Baseline patient characteristics, surgical characteristics, and micronutrient levels by
treatment group for those that received surgery and returned for at least one follow-
up appointment.
Placebo (n ¼ 85) F&V (n ¼ 98)
Age, years 28 [24, 33] 28.5 [23, 34]
Male, n (%) 32 (37.7) 39 (40.0)
Smoking status, n (%)
Never 54 (63.5) 56 (57.1)
Ex-smoker 18 (21.2) 13 (13.3)
Current smoker 13 (15.3) 29 (29.6)
Index of multiple deprivation 35.5 (18.1) 33.6 (17.2)
Systolic Blood Pressure (mmHg) 128.0 (13.5) 127.2 (14.3)
Diastolic Blood Pressure (mmHg) 80.4 (12.5) 79.2 (10.3)
Weight (kg) 76.0 (18.9) 75.9 (17.0)
Height (m) 1.70 (0.11) 1.71 (0.09)
BMI 25.1 [22.2, 29.0] 24.7 [22.0, 29.5]
Race, n (%)
White 51 (60.0) 66 (67.4)
Asian 23 (27.1) 19 (19.4)
Black 7 (8.2) 7 (7.1)
Other 4 (4.7) 6 (6.1)
Baseline micronutrientsa
Vitamin C (mmol/L) 52.9 (24.3) 61.4 (27.1)
Lutein (mmol/L) 0.19 [0.14, 0.25] 0.20 [0.15, 0.26]
Zeaxanthin (mmol/L) 0.05 [0.04, 0.07] 0.05 [0.04, 0.07]
Cryptoxanthin (mmol/L) 0.09 [0.07, 0.17] 0.11 [0.08, 0.16]
Lycopene (mmol/L) 0.91 [0.55, 1.18] 0.77 [0.57, 1.10]
a-Carotene (mmol/L) 0.08 [0.04, 0.13] 0.08 [0.06, 0.11]
b-Carotene (mmol/L) 0.31 [0.18, 0.52] 0.32 [0.25, 0.52]
a-Tocopherol (mmol/L) 19.0 [16.4, 23.1] 20.0 [17.0, 23.4]
Retinol (mmol/L) 1.23 [1.06, 1.49] 1.25 [1.01, 1.48]
SMAC (mmol/L Teq) 382 [325, 447] 383 [346, 441]
Surgical measures
Bone removal, n (%)
Minor 24 (28.2) 43 (43.9)
Moderate 49 (57.7) 47 (48.0)
Severe 12 (14.1) 8 (8.2)
Oral hygiene
Good/very good 70 (82.4) 85 (86.7)
Fair/poor/very poor 13 (15.3) 10 (10.2)
Missing 2 (2.3) 3 (3.1)
Length of surgery (minutes) 13 [9, 20] 12 [8, 17]
Tooth sectioning, n (%) 57 (67.1) 54 (55.1)
Pre-operative CHX rinse, n (%) 42 (49.4) 45 (45.9)
Lingual ﬂap, n (%) 22 (25.9) 18 (18.4)
Envelope ﬂap, n (%) 50 (58.8) 61 (62.2)
Continuous variables are presented as mean (SD) or median [IQR].
a There is missing baseline data for all micronutrients for 2 patients assigned to
placebo and 4 patients assigned to F&V.
P. Gorecki et al. / Clinical Nutrition xxx (2017) 1e8 5active and placebo groups in terms of compliance (Supplemental
Table 3). Thirteen patients stopped taking the capsules because of
AEs (placebo ¼ 7, F&V ¼ 6).
3.2. Main results
3.2.1. Primary endpoint
PoSSe scale data was available for 172 patients (Table 3) and
showed that, on average, patients in the active intervention group
(mean 33.8, SD 15.5) reported less postoperative morbidity during
the ﬁrst postoperative week than patients in the placebo group
(mean 38.4, SD 16.4, unadjusted mean difference in PoSSe
score: 4.59, 95% CIp: 9.37 to 0.18, p ¼ 0.059). When the treat-
ment effect estimate was adjusted for baseline age, BMI, gender,
race, and smoking status, the mean difference between PoSSe
scores was 5.57 points (95% CI: 10.48 to 0.66, p ¼ 0.027).
Additional adjustment for surgical characteristics, i.e. amount of
bone removal, length of surgery, tooth sectioning, and pre-
operative chlorhexidine rinse, rendered a mean difference be-
tween PoSSe scores of 3.97 for active compared to placebo group
(95% CI: 8.79 to 0.84, p ¼ 0.105).Please cite this article in press as: Gorecki P, et al., Perioperative supple
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Comparing active to placebo groups, the analysis of separate
PoSSe domains shows signiﬁcantly lower impact for pain in un-
adjusted analyses, and signiﬁcantly lower impacts for pain, eating
and sickness in analyses adjusted for baseline characteristics.
Following adjustments for surgical characteristics, none of the
differences between subscale impacts were statistically signiﬁcant
(Table 3). Trismus (limitation of mouth opening) on postoperative
day 2 was lower in the active intervention compared to placebo
group by3.1 mm (95% CI:6.1 to0.1, p¼ 0.042). Adjustment for
baseline characteristics resulted in 3.7 mm (95% CI: 6.6 to 0.7,
p ¼ 0.016). However, additional adjustment for surgical factors
resulted in an attenuated difference in trismus between groups
(2.7 mm, 95% CI: 5.6 to 0.2, p ¼ 0.069) (Table 3). One week
following surgery, the estimate of a difference in trismus between
active and placebo decreased to less than 1.5 mm and showed no
statistical signiﬁcance for any analysis.
The mean pain score for postoperative days 1e6 also revealed a
statistically signiﬁcant difference between groups in all analyses,
with a higher mean pain score by a mean of 8.5 mm for the control
group compared to the active group when adjusting for both
baseline and surgical factors (95% CI: 15.5 to 1.6, p ¼ 0.017). The
conclusion was the same after imputation.
There was a 46% lower risk of VAS score over 50% on follow-up
day 2 in the active group after adjusting for baseline and surgical
covariates with a 95% CI: 0.32 to 0.89, which was statistically sig-
niﬁcant at the 5% signiﬁcance level (p ¼ 0.015).
Other secondary outcomes were not statistically signiﬁcantly
different at the 5% signiﬁcance level between treatment groups
(Table 3).
3.2.3. Micronutrient levels
The levels of vitamin C, a-Tocopherol, a-Carotene, and b-Caro-
tene were statistically signiﬁcantly higher in the F&V group
compared to placebo, following 10 weeks of supplementation and
having adjusted for their respective baseline levels (Table 4). For
active compared to placebo between baseline and surgery, themean
difference in vitamin C was 23.6 mmol/L (95% CI: 17.1 to 30.1,
p < 0.001), the mean difference for b-Carotenewas 1.13 mmol/L (95%
CI: 0.88 to 1.38, p< 0.001), themean difference for a-Tocopherol was
2.86 mmol/L (95% CI: 1.69 to 4.05, p < 0.001), and the mean differ-
ence in a-Carotenewas 0.02 mmol/L (95% CI: 0.00 to 0.03, p¼ 0.045).
For these AMs, the treatment effect estimates were also statistically
signiﬁcant at day 2 and day 7 for active compared to placebo after
adjusting for the baseline levels. There were no statistically signiﬁ-
cant differences between treatment groups for the other micro-
nutrients. Estimated serum SMAC was signiﬁcantly higher in the
active compared to the placebo group at the time of surgery.
3.2.4. Adverse events
In total 14 AEs, which were classiﬁed as having a “possible” or
“probable” relationship with the intervention, were recorded. The
vast majority of these (n ¼ 11) were gastrointestinal (GI)q upset;
mainly nausea and bloating. Other possible AEs were “itchiness”
(n ¼ 2) and “tiredness” (n ¼ 1). All of the patients with GI upset
stopped taking the supplements, as did one patient with itchiness
(50%) and the one patient with reported tiredness. Overall, 57% of
AEs were reported in the placebo group (GI upset n ¼ 5 (45%),
itchiness n ¼ 2 (100%), tiredness n ¼ 1 (100%)).
4. Discussion
Clinical research on the effect of perioperative nutritional sup-
plementation onwound healing has focussed mainly on critically ill
patients and/or patients with chronic wounds, such as pressurementation with a fruit and vegetable juice powder concentrate and
d clinical trial, Clinical Nutrition (2017), http://dx.doi.org/10.1016/
Table 3
Comparison of standardised PoSSe score at 7 days post-surgery, PoSSe subscale scores and other secondary outcomes between treatment groups.
Unadjusted treatment
effect estimate (95% CI), p-value
Adjusted treatment
effect estimate (95% CI), p-valuea
Adjusted treatment effect
estimate (95% CI), p-valueb
PoSSe score at 7 days post-surgeryc 4.6 (9.4 to 0.2), 0.059 5.6 (10.5 to 0.7), 0.027 4.0 (8.8 to 0.8), 0.105
PoSSe subscales:c
Eating 0.25 (0.55 to 0.05), 0.098 0.32 (0.63 to 0.02), 0.04 0.23 (0.53 to 0.07), 0.128
Speech 0.10 (0.40 to 0.20), 0.526 0.10 (0.40 to 0.20), 0.517 0.08 (0.39 to 0.23), 0.609
Sensation 0.17 (0.32 to 0.28), 0.910 0.03 (0.32 to 0.27), 0.867 0.01 (0.30 to 0.31), 0.953
Appearance 0.16 (0.46 to 0.14), 0.286 0.22 (0.54 to 0.09), 0.158 0.14 (0.45 to 0.18), 0.395
Pain 0.31 (0.61 to 0.01), 0.041 0.33 (0.64 to 0.02), 0.038 0.26 (0.58 to 0.33), 0.110
Sickness 0.22 (0.52 to 0.08), 0.151 0.31 (0.61 to 0.16), 0.039 0.26 (0.56 to 0.05), 0.099
Interaction 0.21 (0.51 to 0.08), 0.159 0.24 (0.55 to 0.08), 0.137 0.15 (0.46 to 0.15), 0.322
Trismus at day 2 (mm)c 3.11 (6.11 to 0.11), 0.042 3.66 (6.63 to 0.68), 0.016 2.70 (5.61 to 0.21), 0.069
Trismus at day 7 (mm)c 1.43 (4.50 to 1.64), 0.360 1.85 (5.01 to 1.30), 0.247 0.50 (3.57 to 2.57), 0.749
Mean pain score for days 1e6c 8.49 (15.2 to 1.81), 0.013 9.31 (16.2 to 2.43), 0.008 8.51 (15.5 to 1.55), 0.017
Total consumption of analgesics (day 1e6)c 2.27 (5.85 to 1.31), 0.212 3.02 (6.64 to 0.60), 0.101 2.38 (6.11 to 1.36), 0.211
Proportion patients pain score>50% VAS on day 2d 0.58 (0.35 to 0.95), 0.030 0.54 (0.33 to 0.90), 0.017 0.54 (0.32 to 0.89), 0.015
Proportion patients pain score >50% VAS on day 6d 0.72 (0.40 to 1.28), 0.259 0.65 (0.37 to 1.14), 0.133 0.71 (0.40 to 1.24), 0.227
Proportion of patients with absolute increase of 20%
on VAS on any day from day 4 to day 6, compared
to the previous dayd
0.55 (0.29 to 1.06), 0.073 0.56 (0.28 to 1.10), 0.092 0.60 (0.30 to 1.20), 0.149
PoSSe subscales are standardised to have SD ¼ 1.
a Treatment effect estimate is adjusted for smoking, age, gender, ethnicity and BMI.
b Treatment effect estimate is adjusted for smoking, age, gender, ethnicity and BMI, and amount of bone removal, length of surgery, tooth sectioning, and pre-operative
chlorhexidine rinse.
c Linear regression model.
d Poisson regression model so treatment effect estimate is a risk ratio.
Table 4
Effect of treatment on micronutrient levels.
Placebo, Median [IQR] Active, Median [IQR] Mean difference (95% CI), p-value
Vitamin C, mmol/L
Surgery 54.0 [31.4, 70.5] 80.7 [62.5, 98.6] 23.6 (17.1 to 30.1), <0.001
2-day post-op review 49.1 [26.1, 68.4] 74.8 [61.9, 92.5] 23.1 (16.2 to 30.0), <0.001
7-day post-op review 46.8 [26.9, 66.3] 76.1 [59.6, 93.0] 24.1 (17.5 to 30.8), <0.001
a-Tocopherol, mmol/L
Surgery 19.7 [16.7, 22.9] 22.8 [19.6, 28.1] 2.86 (1.69 to 4.05), <0.001
2-day post-op review 18.7 [16.4, 21.6] 21.9 [19.1, 27.2] 2.57 (1.53 to 3.62), <0.001
7-day post-op review 19.7 [16.3, 22.1] 23.2 [20.0, 28.0] 3.14 (2.10 to 4.17), <0.001
b-Carotene, mmol/L
Surgery 0.31 [0.18, 0.44] 1.11 [0.55, 1.95] 1.13 (0.88 to 1.38), <0.001
2-day post-op review 0.28 [0.17, 0.44] 1.08 [0.58, 1.82] 1.04 (0.82 to 1.27), <0.001
7-day post-op review 0.27 [0.18, 0.44] 1.15 [0.51, 1.74] 1.04 (0.81 to 1.27), <0.001
a-Carotene, mmol/L
Surgery 0.08 [0.05, 0.11] 0.08 [0.06, 0.12] 0.02 (0.00 to 0.03), 0.045
2-day post-op review 0.07 [0.04, 0.11] 0.08 [0.06, 0.12] 0.02 (0.00 to 0.03), 0.024
7-day post-op review 0.07 [0.04, 0.11] 0.08 [0.06, 0.12] 0.02 (0.00 to 0.03), 0.037
Retinol, mmol/L
Surgery 1.28 [1.01, 1.48] 1.26 [1.05, 1.49] 0.05 (0.01 to 0.10), 0.102
2-day post-op review 1.07 [0.86, 1.30] 1.08 [0.92, 1.32] 0.05 (0.01 to 0.11), 0.080
7-day post-op review 1.20 [0.99, 1.38] 1.25 [1.01, 1.49] 0.06 (0.00 to 0.13), 0.061
Lutein, mmol/L
Surgery 0.19 [0.15, 0.26] 0.20 [0.14, 0.26] 0.02 (0.03 to 0.00), 0.061
2-day post-op review 0.18 [0.14, 0.24] 0.19 [0.13, 0.24] 0.01 (0.03 to 0.00), 0.130
7-day post-op review 0.18 [0.14, 0.24] 0.19 [0.14, 0.24] 0.01 (0.02 to 0.01), 0.374
Lycopene, mmol/L
Surgery 0.80 [0.54, 1.17] 0.74 [0.52, 1.01] 0.02 (0.07 to 0.11), 0.670
2-day post-op review 0.78 [0.56, 1.13] 0.72 [0.49, 0.97] 0.00 (0.10 to 0.10), 0.980
7-day post-op review 0.73 [0.50, 1.13] 0.65 [0.49, 1.04] 0.03 (0.14 to 0.07), 0.534
Cryptoxanthin, mmol/L
Surgery 0.11 [0.07, 0.17] 0.11 [0.07, 0.19] 0.02 (0.01 to 0.05), 0.180
2-day post-op review 0.10 [0.06, 0.16] 0.11 [0.07, 0.19] 0.02 (0.00 to 0.05), 0.111
7-day post-op review 0.10 [0.06, 0.15] 0.10 [0.08, 0.19] 0.03 (0.00 to 0.05), 0.020
Zeaxanthin, mmol/L
Surgery 0.06 [0.04, 0.07] 0.05 [0.04, 0.07] 0.00 (0.01 to 0.01), 0.874
2-day post-op review 0.05 [0.04, 0.07] 0.05 [0.04, 0.06] 0.00 (0.01 to 0.01), 0.955
7-day post-op review 0.05 [0.04, 0.07] 0.05 [0.04, 0.06] 0.00 (0.00 to 0.01), 0.489
SMAC, mmol/L Teq
Surgery 364 [317, 422] 388 [338, 451] 18.4 (4.2 to 32.6), 0.012
Day of surgery n ¼ 82 for placebo and n ¼ 93 for active; day 2 n ¼ 79 for placebo and n ¼ 92 for active; day 7 n ¼ 78 for placebo and n ¼ 82 for active.
Treatment effect is adjusted for baseline measurements of micronutrient levels.
SMAC e Small molecule antioxidant capacity, micromoles of Trolox equivalents/litre (mmol/L Teq).
SMAC not available for postoperative day 2 and day 7.
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P. Gorecki et al. / Clinical Nutrition xxx (2017) 1e8 7ulcers [15]. Although the role of AMs in wound healing is widely
recognised [16], there is a paucity of data on the potential effect of
micronutrient supplementation on the healing of surgical wounds.
Lower third molar surgery is a very common surgical procedure
associated with signiﬁcant postoperative morbidity and is also an
attractive surgical model for clinical research [17e20]. Postoperative
sequelae include pain, swelling, trismus (reduced mouth opening)
for several days and occur as a result of the inﬂammatory response
to the surgical trauma to bone and soft tissues as well as the mi-
crobial challenge to the intraoral wound. These sequelae lead to
functional incapacity affecting QoL. This randomised, double-blind,
placebo-controlled clinical trial examined whether the pre- and
perioperative intake of a commercially available fruit and vegetable
pulp and juice powder concentrate (Juice Plusþ®) was associated
with improved QoL and reduced morbidity postoperatively. The
results suggest that the intervention may have a modest beneﬁt in
terms of overall QoL, trismus and postoperative pain.
These results need to be cautiously interpreted in light of the
limitations of this study. Firstly, the supplements evaluated in the
present study are made from a wide variety of different fruit and
vegetables and are enriched with carotenoids and vitamins. It is
therefore unclear which speciﬁc constituents or combination of
constituents would be responsible for any observed effect. How-
ever, evidence suggests that the beneﬁcial effects of higher fruit and
vegetable consumption on inﬂammatory diseases are attributable
to the additive and synergistic interactions of the plethora of phy-
tochemicals present in whole foods by targeting multiple signal
transduction pathways [21], and these mechanisms could be un-
derpinning the effects observed in the present study. The supple-
ments evaluated here have been shown to contain a substantial
amount of different (poly)phenolic compounds, demonstrating that
the capsules preserve these compounds as they occur in the large
variety of source plants used in their manufacture [22]. Alterna-
tively, the observed effect may be attributable to a few or a single
speciﬁc constituent. Serum concentrations of a-tocopherol, b-
carotene and vitamin C increased signiﬁcantly over 10 weeks of
supplement intake in the active group, and marked differences
between groups in the plasma concentrations of these micro-
nutrients were evident at the time of surgery, resulting in higher
estimated small molecule antioxidant capacity in serum (Table 4).
However, whether or not the observed effects are a result of
increased antioxidant capacity is uncertain, and future research
would ideally assess markers of oxidative stress in the local wound
environment. Vitamin C plays a crucial role in various wound
healing processes [16,23], and emerging evidence suggests that
vitamin C, possibly in concert with vitamin E, may have anti-
nociceptive effects, as demonstrated in different pain models
[24e27]. Recent clinical studies suggest that administration of
vitamin C can alleviate inﬂammatory pain, including postoperative
pain [28e30]. In the present study, the strongest effects were
observed for the secondary pain endpoints, with patients in the
verum group being almost half as likely to experience moderate to
severe pain 2 days after surgery than patients in the placebo group,
and reduced pain levels could directly or indirectly explain the
effects on other endpoints.
Secondly, the observed p-values for the primary endpoint, as
well as several secondary endpoints hover around the 5% signiﬁ-
cance level, depending on if and what baseline and surgical char-
acteristics are included in the statistical models. In the absence of
anchor-based estimates of a minimally important difference in
QoL following third molar surgery, the sample size was set to
achieve 90% power to detect a standardised effect size of 0.5 [12].
However, research on other patient reported outcomes suggests
that standardised effect sizes of 0.2e0.3 would represent small but
important, i.e., clinically signiﬁcant differences [31]. The effect sizesPlease cite this article in press as: Gorecki P, et al., Perioperative supple
postsurgical morbidity: A double-blind, randomised, placebo-controlle
j.clnu.2017.08.004observed in this trial for QoL (including the eating, sickness and
pain subscales) and the secondary endpoints of pain and trismus
were in that range or slightly larger. However, our study lacked
power to detect differences smaller than 0.5 and the possibility that
the observed differences are due to chance must be acknowledged.
Loss to follow-up before surgery was relatively high at 19%, but
was unlikely to be related to the intervention and cannot have been
related to the study outcomes as these patients did not receive
surgery. Current smoking was the only baseline characteristic that
was signiﬁcantly associated with patients not attending for surgery,
possibly a marker of lower compliance, which has also been re-
ported in the context of observational research [32e34]. Our sec-
ondary analyses adjusted for surgical factors deemed important for
surgical morbidity, including markers of surgical complexity/
severity of trauma (bone removal, tooth sectioning, duration of
surgery) and pre-operative chlorhexidine rinse [35]. While these
are variables collected after randomisation, the difﬁculty of sur-
gery/surgical trauma or decision to use pre-operative chlorhexidine
rinse cannot have reasonably been affected by group assignment in
this double-blind trial, and these statistical adjustments allow
appreciation of the effect of chance differences between groups. As
can be expected for a moderately sized trial, some imbalances were
observed at baseline, including a moderately higher vitamin C
concentration in the active group. In a post-hoc sensitivity analysis,
adjustment for baseline vitamin C concentrations yielded similar
estimates (results not shown).
Finally, patients in the present study received supplements for a
relatively long period of 10 weeks preoperatively. Nutritional sup-
plement formulations such as the one evaluated in this study are
usually taken long-term, and in the absence of short-term phar-
macokinetic data we were conﬁdent that steady state would be
achieved by 10 weeks [36]. However, such preoperative supple-
mentation for 10 weeks would be difﬁcult or impossible to imple-
ment in many clinical scenarios, and short-term supplementation
should therefore be evaluated in future studies. Notwithstanding
these uncertainties and limitations, our results should encourage
further research into the possible effects of nutritional supplements
and their constituents on postsurgical pain, morbidity and wound
healing. In conclusion, perioperative supplementation with a
commercially available fruit and vegetable pulp and juice powder
concentrate (Juice Plusþ®) may reduce postoperative morbidity
and improve QoL during recovery after lower third molar surgery.
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